Answers are grounded in this paper and cite their sources.
SUMMARY The evolution of clinical practice in the care of extremely low birth weight infants continues to affect their number of transfusions. Advancements such as improved ventilation and treatment of preterm lung disease, the development of pediatric laboratory equipment and microsampling techniques, and the use of alternatives to blood products such as human recombinant erythropoietin (rHuEPO) have all improved transfusion practices in neonatology. EPO has been studied extensively as treatment for a variety of anemias in adults and children. Following in vitro studies of the anemia of prematurity that showed the primary etiology to be decreased EPO concentrations, clinical trials evaluated the administration of EPO to preterm infants to treat the anemia of prematurity. Recent studies have focused on the administration of EPO in the first weeks of life to alleviate the anemia caused by excessive phlebotomy losses, and to prevent the anemia of prematurity. It is likely that EPO administration in combination with instituting rigorous transfusion guidelines and decreasing phlebotomy losses will have the greatest impact in decreasing transfusion requirements in all preterm and term neonates, regardless of the etiology of their anemia.
No takes yet. Share an insight, caveat, or question.
Robin K. Ohls (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: